On the afternoon of December 18, Wang Rong, member of the Standing CPC Committee of Guangdong Province and CPC Secretary of Shenzhen City, inspected CR Sanjiu in the company of Li Huanan and Lv Yuyin, leaders of Shenzhen city.

In the Exhibition Center, heads of CR Sanjiu outlined the development history of CR Sanjiu, especially the great changes and achievements the enterprise has experienced in the past five years since the merger with CR. Over the past five years, CR Sanjiu has received support in every aspects from CR Group, which relieved CR Sanjiu of its burden and provided it with development opportunities. The Company has attained breakthrough growth in its operating results, fundamental organizational innovation and constant strategic adjustment, with its efforts highly focused on pharmaceutical business. From January to September, the Company realized a total business income of 5.603 billion yuan, a year-on-year increase of 13.96%, and a net profit of 875 million yuan, a year-on-year increase of 17.32%. The company saw a net profit of 274 million yuan in the third quarter alone, a year-on-year growth of 21.57%. The company has established a clear strategy and proposed a development target of “seeking to become a leader of the OTC market and an innovator of the prescribed Chinese medicine market.”

Wang made positive comments on the gratifying achievements attained by the company and hoped that CR Sanjiu will focus on R&D innovation and quality of new products, and, seizing the opportunities brought by the new national reform in the medicine sector and following the strategic guidance of the Group and CR Pharmaceuticals, constantly overcome new challenges and seek to attain excellent achievements for greater development. He also spoke highly of CR Sanjiu’s business philosophy of “care, responsibility and excellence", its caring the health of the general population and performing social responsibilities.